CN114641279A - 一种能够沉默Pcsk9蛋白的siRNA、其纳米递送系统及应用 - Google Patents

一种能够沉默Pcsk9蛋白的siRNA、其纳米递送系统及应用 Download PDF

Info

Publication number
CN114641279A
CN114641279A CN202080072674.6A CN202080072674A CN114641279A CN 114641279 A CN114641279 A CN 114641279A CN 202080072674 A CN202080072674 A CN 202080072674A CN 114641279 A CN114641279 A CN 114641279A
Authority
CN
China
Prior art keywords
sirna
nanocapsule
parts
nano
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080072674.6A
Other languages
English (en)
Inventor
张灵敏
余细勇
林忠晓
张燕芬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Medical University
Original Assignee
Guangzhou Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Medical University filed Critical Guangzhou Medical University
Publication of CN114641279A publication Critical patent/CN114641279A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

一种能够沉默PCSK9蛋白的siRNA，所述siRNA的正义链氨基酸序列为5′‑UUCCGAAUAAACUCCAGGC‑3′,反义链氨基酸序列为5′‑GCCUGGAGUUUAUUCGGAA‑3′，以及其纳米递送系统、制备方法和应用。所述方法具有较高的转染效果并能维持长时间作用，对于降血脂具有较好的治疗效果，适用于降血脂的基因治疗。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN202080072674.6A 2019-10-25 2020-08-07 一种能够沉默Pcsk9蛋白的siRNA、其纳米递送系统及应用 Pending CN114641279A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019110223850 2019-10-25
CN201911022385.0A CN110638788A (zh) 2019-10-25 2019-10-25 一种能够沉默Pcsk9蛋白的siRNA、其纳米递送系统及应用
PCT/CN2020/107917 WO2021077856A1 (zh) 2019-10-25 2020-08-07 一种能够沉默Pcsk9蛋白的siRNA、其纳米递送系统及应用

Publications (1)

Publication Number Publication Date
CN114641279A true CN114641279A (zh) 2022-06-17

Family

ID=68994786

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911022385.0A Pending CN110638788A (zh) 2019-10-25 2019-10-25 一种能够沉默Pcsk9蛋白的siRNA、其纳米递送系统及应用
CN202080072674.6A Pending CN114641279A (zh) 2019-10-25 2020-08-07 一种能够沉默Pcsk9蛋白的siRNA、其纳米递送系统及应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201911022385.0A Pending CN110638788A (zh) 2019-10-25 2019-10-25 一种能够沉默Pcsk9蛋白的siRNA、其纳米递送系统及应用

Country Status (2)

Country Link
CN (2) CN110638788A (zh)
WO (1) WO2021077856A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108342387B (zh) * 2017-01-24 2021-09-24 谭旭 Pcsk9抑制剂类降血脂药的递送系统和生物制剂
CN111803653B (zh) * 2020-06-27 2022-04-15 苏州大学 可脱混合细胞膜包被的基因递送体系及其制备方法与应用
CN112451504B (zh) * 2020-11-09 2022-10-18 四川大学华西医院 一种载EBV-LMP2 mRNA的核-壳纳米粒的制备方法及应用
WO2023051822A1 (zh) * 2021-09-30 2023-04-06 北京安龙生物医药有限公司 用于治疗与pcsk9相关疾病的靶向寡核苷酸

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108553650A (zh) * 2018-03-28 2018-09-21 暨南大学 一种仿生纳米红细胞基因载体及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011013421A (es) * 2009-06-15 2012-03-16 Alnylam Pharmaceuticals Inc Arnds formulado con lipido de direccionamiento del gen pcsk9.
WO2010147992A1 (en) * 2009-06-15 2010-12-23 Alnylam Pharmaceuticals, Inc. Methods for increasing efficacy of lipid formulated sirna
WO2011038031A1 (en) * 2009-09-22 2011-03-31 Alnylam Pharmaceuticals, Inc. Dual targeting sirna agents
US9080171B2 (en) * 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
EP3336187A1 (en) * 2012-12-05 2018-06-20 Alnylam Pharmaceuticals, Inc. Pcsk9 irna compositions and methods of use thereof
CA2905108C (en) * 2013-03-14 2021-12-07 Julie HUGHES Cholestosome vesicles for incorporation of molecules into chylomicrons
WO2016205009A1 (en) * 2015-06-19 2016-12-22 The Regents Of The University Of California Treating infection by a platelet-targeting microbe using nanoparticles
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
CN105497912A (zh) * 2016-01-21 2016-04-20 华东师范大学 红细胞膜包裹的酸敏感高分子前药纳米递药系统的制备方法及用途
CN108066763A (zh) * 2017-12-21 2018-05-25 陈敏 Pcsk9抑制剂在制备治疗t细胞介导的炎症免疫性疾病药中的应用
CN109432048B (zh) * 2018-11-22 2021-03-19 东华大学 一种血小板膜包裹载药多孔纳米颗粒及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108553650A (zh) * 2018-03-28 2018-09-21 暨南大学 一种仿生纳米红细胞基因载体及其制备方法与应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DITTE KROHN JENSEN等: "Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA", 《JOURNAL OF CONTROLLED RELEASE》, vol. 157, pages 141 - 148, XP028443380, DOI: 10.1016/j.jconrel.2011.08.011 *
LEE等: "Abasic pivot substitution harnesses target specificity of RNA interference", 《NATURE COMMUNICATIONS》, vol. 6, pages 1 - 14 *
ZEJUN XU等: "Polyester based nanovehicles for siRNA delivery", 《MATERIALS SCIENCE & ENGINEERING C》, vol. 92, pages 1006 - 1015, XP085462487, DOI: 10.1016/j.msec.2018.05.031 *
姚慧敏著: "靶向定位给药系统及评价方法", 吉林大学出版社, pages: 29 - 30 *

Also Published As

Publication number Publication date
WO2021077856A1 (zh) 2021-04-29
CN110638788A (zh) 2020-01-03

Similar Documents

Publication Publication Date Title
US20210212948A1 (en) Nanovesicles derived from cell membrane, and use thereof
CN114641279A (zh) 一种能够沉默Pcsk9蛋白的siRNA、其纳米递送系统及应用
JP6023126B2 (ja) 標的遺伝子の発現を抑制する組成物
Pei et al. Exosome membrane-modified M2 macrophages targeted nanomedicine: Treatment for allergic asthma
US10322089B2 (en) Nanoparticles, nanoparticle delivery methods, and systems of delivery
KR20170140377A (ko) 유전자 치료제의 표적화된 약물 전달을 위한 표적화된 나노캐리어
CN102497887A (zh) 递送遗传物质的组合物
Zhang et al. Emerging role of exosomes in retinal diseases
JP2014177477A (ja) 標的遺伝子の発現を抑制する組成物
Zadory et al. Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression
US11560575B2 (en) High efficient delivery of plasmid DNA into human and vertebrate primary cells in vitro and in vivo by nanocomplexes
Zhou et al. MSC-exosomes in regenerative medicine
Su et al. MicroRNA-195 liposomes for therapy of Alzheimer's disease
WO2019157316A2 (en) Methods and devices for the isolation of subcellular components
JP5952197B2 (ja) 標的遺伝子の発現を抑制する組成物
CN117018229B (zh) 过表达Clec1b蛋白质细胞膜在制备膝骨关节炎药物的用途
JP5872898B2 (ja) 標的遺伝子の発現を抑制する組成物
CN117018229A (zh) 过表达Clec1b蛋白质细胞膜在制备膝骨关节炎药物的用途
EP4334445A1 (en) Engineered extracellular vesicles
US20120244210A1 (en) Composition for suppressing expression of target gene
US20120207818A1 (en) Composition for suppressing expression of target gene
KR101814879B1 (ko) 유전자 전달체 및 그 제조방법
WO2011049059A1 (ja) Ｒｎａ内包キャリア組成物
CN115887679A (zh) 一种基因-化疗纳米药物共递送系统、其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination